Company Information
Company Profile
Cash Flow Statement
Profit & Loss
Financial Position
Financial Ratio
Industry 制造业
Company Introduction 2010年1月，潘柯、庄承锐签署了《江苏亚虹医药科技有限公司章程》，共同出资设立了亚虹有限，约定亚虹有限设立时的注册资本为600万元。2010年2月，江苏省工商行政管理局签发《名称预先核准通知书》（（12000055）名称预先登记[2010]第01290011号），同意预先核准公司名称“江苏亚虹医药科技有限公司”。2010年3月，江苏省泰州工商行政管理局出具了《公司准予设立登记通知书》，核准上述设立事项，并核发《企业法人营业执照》。 公司确认以截至2020年10月31日经审计确认的净资产按照2.039674：1的比例折合股份公司的股份总额4.6亿股，每股面值为人民币1元，股份公司的注册资本（股本总额）为人民币4.6亿元，净资产折股后超出股份公司注册资本部分计入股份公司的资本公积。立信会计师事务所（特殊普通合伙）已于2020年12月14日出具了信会师报字[2020]第ZA16016号《验资报告》，对发起人出资予以验证。公司已于2020年12月11日在泰州市市场监督管理局完成了工商变更登记手续，并换领了统一社会信用代码为91321291552450798T的《营业执照》。 发行人是即将进入商业化阶段、专注于泌尿生殖系统（UrogenitalSystem）肿瘤及其它重大疾病领域的全球化创新药公司。秉承“改善人类健康，让生命更有尊严”的企业使命，发行人立志成为在专注治疗领域集研发、生产和商业化为一体的国际领先制药企业，为中国和全球患者提供最佳的诊疗一体化解决方案。 发行人坚持以创新技术和产品为核心驱动力，通过内部完善的研发体系、三大核心技术平台和全球药物开发经验专长，深入探索药物作用机理，高效率筛选评价候选药物，致力于在专注治疗领域推出全球首创（First-in-Class）药物及存在巨大未被满足治疗需求的创新药物。 同时，发行人通过自主研发和战略合作，围绕泌尿生殖系统疾病进行产品管线的深度布局。发行人高度关注专注领域的技术前沿和治疗发展趋势，洞察并挖掘未被满足的临床需求，前瞻性地进行产品规划和生命周期管理，打造从疾病诊断到治疗的优势产品组合，从而造福更多的中国和全球患者。
Main Business 专注于泌尿生殖系统（Urogenital System）肿瘤及其它重大疾病领域的全球化创新药
Legal Representative PAN KE
Top Executives
董事长：PAN KE
董事：杨明远,李显显,陈文德,江新明,ZHUANG CHENGFENG JOHN
独立董事：黄彬,张炳辉,王文宁
Top 5 Shareholder
Shareholder name Nature Holding Date
PAN KE限售股+流通A股22.83%30/09/2024
Pan－Scientific Holdings Co.,Ltd.限售股5.59%30/09/2024
北京龙磐健康医疗投资中心（有限合伙）流通A股4.03%30/09/2024
泰州东虹企业管理中心（有限合伙）限售股2.25%30/09/2024
深圳国中中小企业发展私募股权投资基金合伙企业（有限合伙）流通A股2.10%30/09/2024
Company Secretary 杨明远
Solicitors 北京市嘉源律师事务所
Auditors 立信会计师事务所（特殊普通合伙）
Tel No 021-68583836
Fax No 021-68585281
Website www.asieris.cn
Email securities@asieris.cn
Company Address
Register: 江苏省泰州药城大道一号（创业路东侧、园南路北侧）的新药创制基地二期D幢大楼1009房间
Office: 上海市浦东新区东育路221弄前滩世贸中心（三期）B栋19F
Listing Date 07/01/2022
Shares Capital
Shares Capital: 570,000,000
Total A Share: 570,000,000
Listed A Share: 371,480,498
Non-tradable A Share: 198,519,502
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ -0.700
DPS(RMB)* --
NBV Per Share(RMB)* ¥ 4.189
Market Capitalization(RMB) 2.719B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.